MoonLake Immunotherapeutics Investors Face Lead‑Plaintiff Deadline in Securities Fraud Suits

Investors must act today as cases focus on claims that sonelokimab was touted as superior before Phase 3 results coincided with a steep share collapse.

Overview

Several shareholder-rights firms, including Schall, DJS, Gross, and Portnoy, are urging MLTX investors to contact them about participating or seeking lead-plaintiff status.
Filings cite alleged violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b‑5.
The putative class period spans March 10, 2024 through September 29, 2025, with a lead‑plaintiff motion deadline of December 15, 2025.
Complaints assert MoonLake misled the market by claiming sonelokimab (SLK) was superior to competing therapies, with Phase 3 results described by analysts as “disastrous” and shares dropping nearly 90%.
One notice details technical allegations that SLK targets the same cytokines as BIMZELX and that its Nanobody design did not yield proven clinical advantages, while firms note the class is not yet certified.